|
TCEAL8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.59219999962268E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.14930000003366E-06 |
| Normal-vs-Stage2 |
5.378300E-03 |
| Normal-vs-Stage3 |
2.21680000023206E-07 |
| Normal-vs-Stage4 |
8.33140001432753E-09 |
| Stage1-vs-Stage2 |
5.295800E-01 |
| Stage1-vs-Stage3 |
2.214600E-01 |
| Stage1-vs-Stage4 |
4.521900E-03 |
| Stage2-vs-Stage3 |
1.578150E-01 |
| Stage2-vs-Stage4 |
1.639970E-02 |
| Stage3-vs-Stage4 |
1.234000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.76300000154228E-08 |
| Normal-vs-AfricanAmerican |
1.369770E-02 |
| Normal-vs-Asian |
2.280900E-03 |
| Caucasian-vs-AfricanAmerican |
3.784600E-01 |
| Caucasian-vs-Asian |
1.898600E-01 |
| AfricanAmerican-vs-Asian |
9.404400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65990000000615E-06 |
| Normal-vs-Female |
4.26770000006016E-07 |
| Male-vs-Female |
8.109400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.71795999999169E-05 |
| Normal-vs-Age(41-60Yrs) |
3.2518000000481E-06 |
| Normal-vs-Age(61-80Yrs) |
4.83840000287117E-08 |
| Normal-vs-Age(81-100Yrs) |
6.507900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.991400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.485400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.906200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.767600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.001600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.645600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.030100E-02 |
| Classical-VS-Follicular |
2.893400E-01 |
| Classical-VS-Other |
4.147200E-01 |
| Classical-VS-Normal |
2.91490000026151E-07 |
| Tall-VS-Follicular |
1.049850E-02 |
| Tall-VS-Other |
8.706400E-01 |
| Tall-VS-Normal |
1.80350000045237E-07 |
| Follicular-VS-Other |
3.644000E-01 |
| Follicular-VS-Normal |
7.735900E-03 |
| Other-VS-Normal |
1.459840E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.08659999999728E-05 |
| Normal-vs-N1 |
3.02059999235382E-09 |
| N0-vs-N1 |
3.455700E-03 |
|
|
